Chronic Myelogenous Leukemia
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | BCR::ABL1 | Chronic Myelogenous Leukemia | Asciminib | |
| EMA (1) FDA (1) | ABL1 p.T315I, BCR::ABL1 | Chronic Myelogenous Leukemia | Asciminib | |
| EMA (3) FDA (2) HSE (1) | BCR::ABL1 | Chronic Myelogenous Leukemia | Bosutinib | |
| FDA (3) | BCR::ABL1 | Chronic Myelogenous Leukemia | Dasatinib | |
| FDA (2) | BCR::ABL1 | Chronic Myelogenous Leukemia | Imatinib | |
| FDA (3) | BCR::ABL1 | Chronic Myelogenous Leukemia | Nilotinib | |
| EMA (2) FDA (1) HSE (1) | ABL1 p.T315I | Chronic Myelogenous Leukemia | Ponatinib | |
| EMA (2) | not BCR::ABL1 | Chronic Myelogenous Leukemia | Imatinib | |
| EMA (1) HSE (1) | not BCR::ABL1 | Chronic Myelogenous Leukemia | Asciminib | |
| EMA (3) | not BCR::ABL1 | Chronic Myelogenous Leukemia | Dasatinib | |
| EMA (3) | not BCR::ABL1 | Chronic Myelogenous Leukemia | Nilotinib |